Health

STAT+: Why this startup is taking its AI to predict breast cancer risk directly to patients

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:26 UTC.

Briefings

Everlywell launched a new AI algorithm called Clairity Breast for direct-to-consumer breast cancer risk prediction using mammograms. Patients pay $249 to receive a five-year risk assessment. The algorithm received de novo FDA authorization in May 2026. The company has offered similar at-home tests for over a decade.

Key points

• Everlywell launched Clairity Breast AI for direct-to-consumer breast cancer risk prediction using mammograms.
• Patients pay $249 to receive a five-year risk assessment.

Context

Everlywell has offered at-home lab tests directly to consumers for a decade. This marks a shift from screening for conditions like celiac disease to AI-based medical image analysis.

Limitations

Evidence is limited to a single article snippet from October 2026. Specific patient outcomes, algorithm performance metrics, and long-term regulatory outcomes are not provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 23:23:13 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeic4iubdlg3md7tcczm5fnfjayhsuxsjydx73m7w6vt6nfxwkp2bou